Janssen's Drug Pricing Report Emphasizes Value Of Rebates

As political pressure on pricing continues to build, Janssen's first-ever transparency report notes average list price increase was 8.5% in 2016; annual pricing parties are no longer 'raves,' Raymond James & Associates says.

US-Money-and-Pills_V2_1200x675

Janssen Pharmaceutical Cos.'s report on 2016 price increases shows that the company has kept average list price (wholesale acquisition cost) hikes below 10% for the past five years, while the average net price change (WAC minus rebates, discounts and returns) has ranged from 2.5% to 5.2%.

The Johnson & Johnson unit's first annual US Transparency Report, released Feb. 27, also includes information about...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access